IRIS - Res&Arch Institutional Research Information System - Research & Archive

MANDALA', Mario
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.030
EU - Europa 1.448
AS - Asia 989
Continente sconosciuto - Info sul continente non disponibili 20
SA - Sud America 8
OC - Oceania 7
AF - Africa 1
Totale 6.503
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.025
IE - Irlanda 719
SG - Singapore 493
IT - Italia 455
VN - Vietnam 273
HK - Hong Kong 111
RU - Federazione Russa 89
CN - Cina 58
DE - Germania 43
UA - Ucraina 29
FI - Finlandia 26
SE - Svezia 22
GB - Regno Unito 21
EU - Europa 20
TR - Turchia 18
KR - Corea 17
GR - Grecia 11
FR - Francia 8
NL - Olanda 6
AU - Australia 5
CH - Svizzera 5
CL - Cile 5
UZ - Uzbekistan 5
AT - Austria 4
CA - Canada 4
PL - Polonia 4
JP - Giappone 3
TW - Taiwan 3
BR - Brasile 2
IL - Israele 2
LB - Libano 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
AE - Emirati Arabi Uniti 1
BE - Belgio 1
CZ - Repubblica Ceca 1
EG - Egitto 1
ID - Indonesia 1
IN - India 1
MX - Messico 1
PE - Perù 1
PK - Pakistan 1
RS - Serbia 1
SI - Slovenia 1
Totale 6.503
Salva come PNG Salva come JPEG
Città #
Chandler 947
Dublin 718
Singapore 366
Boardman 285
Dong Ket 273
Altamura 269
Santa Clara 252
San Mateo 234
Medford 216
Princeton 213
Lawrence 207
Andover 187
Wilmington 122
Los Angeles 111
Hong Kong 106
Arezzo 57
Redwood City 57
Des Moines 45
Norwalk 42
San Paolo di Civitate 39
Redmond 23
Ashburn 20
Helsinki 17
Seoul 17
Kocaeli 16
Saint Petersburg 14
Shanghai 11
Jacksonville 10
Perugia 8
Milan 6
Moscow 6
Chicago 5
Florence 5
London 5
Den Haag 4
Lappeenranta 4
Philadelphia 4
St Petersburg 4
Treviso 4
Woodbridge 4
Ancona 3
Falls Church 3
Frankfurt Am Main 3
Guangzhou 3
Kiev 3
Munich 3
New York 3
Padova 3
Santiago 3
Taipei 3
Cleveland 2
Clifton 2
Dallas 2
Dueville 2
Frankfurt am Main 2
Gatchina 2
Hanover 2
Harbin 2
Houston 2
Ivanovo 2
Izmir 2
Las Vegas 2
Ludwigshafen 2
Melbourne 2
Montreal 2
North Bergen 2
Oslo 2
Ostra Vetere 2
Portland 2
Rome 2
San Francisco 2
Shijiazhuang 2
Tel Aviv 2
Terni 2
Tianjin 2
Tokyo 2
Wernigerode 2
Andria 1
Ann Arbor 1
Auckland 1
Augusta 1
Baltimore 1
Beijing 1
Bengaluru 1
Bergamo 1
Brisbane 1
Brussels 1
Cairo 1
Cambridge 1
Cannock 1
Carbonia 1
Changji 1
Changsha 1
Cheyenne 1
Colindale 1
Conshohocken 1
Council Bluffs 1
Cumberland 1
Dalian 1
Dieppe 1
Totale 5.040
Salva come PNG Salva come JPEG
Nome #
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial 55
Chemotherapy-associatedthromboembolic risk in cancer outpatients and effect of nadroparinthromboprophylaxis: results of a retrospective analysis of the PROTECHT study. 52
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 triaL 52
Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism 52
Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial 51
Acute vulvar vestibulitis occurring during chemotherapy with cryptophycin analogue LY355703 51
Acute endocrine effects of interleukin-12 in cancer patients 48
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial 48
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma 48
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial 47
Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling 47
Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin 46
Adjuvant therapy in breast cancer and venous thromboembolism 46
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma 46
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial 46
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial 46
Tissue prognostic biomarkers in primary cutaneous melanoma 45
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management 45
AKT-ions with a TWIST between EMT and MET 44
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival 44
A prospective study on survival in cancer patients with and without venous thromboembolism. 43
Association of socioeconomic status with Breslow thickness and disease-free and overall survival in stage I-II primary cutaneous melanoma 43
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma 43
ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee 42
40. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH 42
Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients 42
Acute dyspnea due to right phrenic palsy during infusional chemotherapy 42
Adjuvant Treatment of Melanoma: Recent Developments and Future Perspectives 41
Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1 41
Analysis of the Expression and Single-Nucleotide Variant Frequencies of the Butyrophilin-like 2 Gene in Patients With Uveal Melanoma 41
Insights Into Genetic Susceptibility to Melanoma by Gene Panel Testing: Potential Pathogenic Variants in ACD, ATM, BAP1, and POT1 40
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial 39
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab 39
Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action 39
Dedifferentiated melanomas: Morpho-phenotypic profile, genetic reprogramming and clinical implications 38
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i 38
Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study 38
GSTM1, P53 and K-ras molecular detection in resectable non-small cell lung cancer by denaturing gradient gel electrophoresis-bronchoalveolar lavage fluid analysis 37
Neoadjuvant imatinib in a locally advanced gastrointestinal stromal tumour (GIST) of the rectum: a rare case of two GISTs within a family without a familial GIST syndrome 37
Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma 36
Adjuvant therapy of colon cancer. State of the art and future perspectives 36
Dehydroepiandrosterone sulfate (DHEAS) secretion in early and advanced solid neoplasms: selective deficiency in metastatic disease 36
Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study 36
Squamoproliferative skin lesion during braf inhibitors:one size does not fit all 36
Efficacy of bromocriptine in the treatment of metastatic breast cancer- and prostate cancer-related hyperprolactinemia 36
Targeted therapy for advanced cutaneous melanoma 35
Venous thromboembolism and cancer: new issues for an old topic 35
Chemotherapy for metastatic breast cancer 35
Diagnostic and therapeutic approaches in Italian hospitals: adjuvant and metastatic therapy in melanoma 35
MelaNostrum: a consensus questionnaire of standardized epidemiologic and clinical variables for melanoma risk assessment by the melanostrum consortiuM 35
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 35
Treatment of venous thromboembolism in cancer patients: The dark side of the moon 35
Is there a right-sided shift for colorectal cancer in women compared with men? 34
Melanoma brain metastases: review of histopathological features and immune-molecular aspects 34
mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition 34
Cutaneous toxicities of BRAF inhibitors: Clinical and pathological challenges and call to action 34
What is the real benefit of adjuvant chemotherapy in the Adjuvant Navelbine International Trialist Association trial? 34
International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer 34
Vinorelbine and carboplatin in inoperable non-small cell lung cancer: a monoinstitutional phase II study 34
Mediastinal lymphoadenopathy in a patient with breast cancer 34
Primary analysis and four-year follow-up of the phase III NIBIT-M2 trial in melanoma patients with brain metastases 34
Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time? 34
Buprenorphine-induced acute respiratory depression during ifosfamide-based chemotherapy 33
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial 33
Paradoxical stimulation of prolactin secretion by L-dopa in metastatic prostate cancer and its possible role in prostate-cancer-related hyperprolactinemia 33
Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup 33
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma 33
Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation-positive melanoma receiving adjuvant vemurafenib 33
Neoadjuvant chemotherapy for patients with liver metastases from colorectal cancer 33
Digital Immunophenotyping Predicts Disease Free and Overall Survival in Early Stage Melanoma Patients 33
Prevalence and Clinical Impact of SARS-CoV-2 Silent Carriers Among Actively Treated Patients with Cancer During the COVID-19 Pandemic 32
Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants? 32
Single-agent epirubicin as primary chemotherapy in T2-T3, N0-N2, M0 breast carcinoma: 6-year follow-up 32
Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status 32
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program 32
Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis 32
HER2/neu expression and hormonal therapy in early breast cancer: can muddy waters become clear? 32
Bisphosphonates and metastatic bone disease 32
The extension of disease is associated to an increased risk of venous thromboembolism (VTE) in patients with gastrointestinal (GI) carcinoma 32
A case of sudden brain metastases progression after temporary targeted therapy discontinuation: when to regret a drug holiday 32
Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS) 32
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. 31
Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: A multicenter international retrospective study 31
An open-label, multicentre safety study of vemurafenib in patients with BRAF(V600)-mutant metastatic melanoma: final analysis and a validated prognostic scoring system 31
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial 31
Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAF(V600) mutation-positive melanoma 31
Blood concentrations of tumor necrosis factor-alpha in malignant lymphomas and their decrease as a predictor of disease control in response to low-dose subcutaneous immunotherapy with interleukin-2 31
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial 31
Mitotic rate correlates with sentinel lymph node status and outcome in cutaneous melanoma greater than 1 millimeter in thickness: A multi-institutional study of 1524 cases 31
Clinicopathological predictors of recurrence in nodular and superficial spreading cutaneous melanoma: a multivariate analysis of 214 cases 31
Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the 'GISCAD-alternating schedule' study findings 30
PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p 30
The density and spatial tissue distribution of CD8+ and CD163+immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors 30
Unexpected right phrenic nerve injury during 5-fluorouracil continuous infusion plus cisplatin and vinorelbine in breast cancer patients 30
Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study 30
Video meliora proboque sed deteriora sequor: the case of thromboprophylaxis in hospitalized cancer patients 30
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma 30
Chemoradiotherapy for rectal cancer 30
Transforming growth factor-beta signaling and regulatory T cells 30
Delayed immune-related adverse events with anti-PD1-based immunotherapy in melanoma 30
Totale 3.720
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.635
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.635
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20207 0 0 0 0 0 0 2 0 3 0 2 0
2020/2021671 0 2 0 2 12 1 270 6 19 51 16 292
2021/20221.193 8 228 9 2 18 7 31 447 9 44 165 225
2022/20233.048 218 524 28 237 275 391 0 166 1.066 9 95 39
2023/2024983 91 154 53 28 18 5 143 9 96 122 99 165
2024/2025963 34 297 25 82 407 118 0 0 0 0 0 0
Totale 6.880